Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers


Luo Yung-Hung,Yang Yi-Ping,Chien Chian-ShiuORCID,Yarmishyn Aliaksandr A.,Ishola Afeez Adekunle,Chien Yueh,Chen Yuh-Min,Huang Tsai-Wang,Lee Kang-Yun,Huang Wen-Chien,Tsai Ping-HsingORCID,Lin Tzu-Wei,Chiou Shih-Hwa,Liu Chao-Yu,Chang Cheng-Chang,Chen Ming-Teh,Wang Mong-LienORCID


Lung cancer (LC) causes the majority of cancer-related deaths. Circular RNAs (circRNAs) were reported to play roles in cancers by targeting pro- and anti-oncogenic miRNAs. However, the mechanisms of circRNAs in LC progression and their prognostic value of treatment response remain unclear. By using next generation sequencing (NGS) of LC cell lines’ transcriptomes, we identified highly overexpressed hsa_circ_0000190 and hsa_circ_000164 as potential biomarkers. By using the highly sensitive RT-ddPCR method, these circRNAs were shown to be secreted by cell lines and were detected in human blood. Clinical validation by RT-ddPCR was carried out on 272 (231 LC patients and 41 controls) blood samples. Higher hsa_circ_0000190 levels were associated with larger tumor size (p < 0.0001), worse histological type of adenocarcinoma (p = 0.0028), later stage (p < 0.0001), more distant metastatic organs (p = 0.0039), extrathoracic metastasis (p = 0.0004), and poor survival (p = 0.047) and prognosis. Using liquid biopsy-based RT-ddPCR, we discovered the correlation between increased hsa_circ_0000190 plasma level (p < 0.0001) and higher programmed death-ligand 1 (PD-L1) level in tumor (p = 0.0283). Notably, long-term follow-up of the immunotherapy treated cases showed that upregulated plasma hsa_circ_0000190 level correlated with poor response to systemic therapy and immunotherapy (p = 0.0002, 0.0058, respectively). Secretory circRNAs are detectable in blood by LB-based RT-ddPCR and may serve as blood-based biomarkers to monitor disease progression and treatment efficacy.


Ministry of Science and Technology, Taiwan

Taipei Veterans General Hospital




Cancer Research,Oncology







Copyright © 2019-2022 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3